Donna Cabral-Lilly

Donna Cabral-Lilly holds extensive experience in the pharmaceutical industry, specializing in CMC program strategy, development, and manufacturing. Currently serving as VP, CMC at atai Life Sciences since October 2024, Donna's prior roles include VP CMC at Onxeo S.A. and ORYN THERAPEUTICS, LLC. Donna's impressive career also features leadership positions at Origin Biosciences, Flex Pharma, Inc., Taaneh, Inc., Celator Pharmaceuticals, Control Delivery Systems, and Elan Pharmaceuticals, with responsibilities ranging from drug product development to quality management systems. Donna earned a PhD in biochemistry and biophysics from Boston University and completed a PostDoctoral Fellowship in Structural Biology at Brandeis University.